Evidence map›Paper›PMID 37101113›Full record

ArticleBMC bioinformatics2023

Magicmol: a light-weighted pipeline for drug-like molecule evolution and quick chemical space exploration.

Lin Chen, Qing Shen, Jungang Lou

Abstract read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lin ChenYangtze Delta Region (Huzhou) Institute of Intelligent Transportation, Huzhou University, Huzhou, China.
Qing ShenYangtze Delta Region (Huzhou) Institute of Intelligent Transportation, Huzhou University, Huzhou, China.
Jungang LouYangtze Delta Region (Huzhou) Institute of Intelligent Transportation, Huzhou University, Huzhou, China. ljg@zjhu.edu.cn.

Funding

Natural Science Foundation of Zhejiang Province LR20F020002Primary Research and Development Plan of Zhejiang Province 2020C01097
6 · The paper itself

Abstract

The flourishment of machine learning and deep learning methods has boosted the development of cheminformatics, especially regarding the application of drug discovery and new material exploration. Lower time and space expenses make it possible for scientists to search the enormous chemical space. Recently, some work combined reinforcement learning strategies with recurrent neural network (RNN)-based models to optimize the property of generated small molecules, which notably improved a batch of critical factors for these candidates. However, a common problem among these RNN-based methods is that several generated molecules have difficulty in synthesizing despite owning higher desired properties such as binding affinity. However, RNN-based framework better reproduces the molecule distribution among the training set than other categories of models during molecule exploration tasks. Thus, to optimize the whole exploration process and make it contribute to the optimization of specified molecules, we devised a light-weighted pipeline called Magicmol; this pipeline has a re-mastered RNN network and utilize SELFIES presentation instead of SMILES. Our backbone model achieved extraordinary performance while reducing the training cost; moreover, we devised reward truncate strategies to eliminate the model collapse problem. Additionally, adopting SELFIES presentation made it possible to combine STONED-SELFIES as a post-processing procedure for specified molecule optimization and quick chemical space exploration.

Indexed as

Deep LearningDrug DesignDrug DiscoveryMachine LearningNeural Networks, ComputerDeep learningDe novo drug designGenerative modelsReinforcement learningSynthetic accessibility

Identifiers

PMID37101113
PMCPMC10132416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.